The pharmaceutical industry is at a turning point.
Pharma v Biotech: New Rules? explores how pricing pressures, policy shifts, and the rise of consumer influence are reshaping the sector, from R&D to commercialization.
Biotech firms, though still somewhat fragile, are now leading the way in capital efficiency and adaptability. Their leaner models offer lessons for Big Pharma, which is slimming down by refining pipelines, outsourcing R&D, and opening direct-to-consumer channels to bypass traditional pricing bottlenecks.
Patients are also gaining influence. Reformulations and delivery innovations, once overlooked, are now among the most valuable pipeline assets.
Whether you’re an investor, strategist, or operator in life sciences, this report offers essential insights into the forces reshaping the future of drug development and access.
Key Insights:
- Modular Biopharma: Discover how asset carve-outs, spinouts, and China-led innovations are reshaping dealmaking and R&D ownership.
- Royalty Financing Boom: Learn how biotechs are unlocking capital through royalty deals with major asset managers.
- Consumer-Led Innovation: See how companies like Corsera Health are packaging familiar science for direct-to-consumer impact.
- Reformulation Renaissance: Explore how delivery upgrades like subcutaneous Keytruda or inhaled TPIP are driving billion-dollar valuations.
